Verteporfin

證據等級: L5

預測適應症: 1 個

Verteporfin: From Choroidal Neovascularization to Mitochondrial Oxidative Phosphorylation Disorder

One-Sentence Summary

Verteporfin is a photosensitizing agent originally used in photodynamic therapy (PDT) for choroidal neovascularization (e.g., wet age-related macular degeneration). The TxGNN model predicts it may be effective for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but this prediction is currently supported by no clinical trials and no literature — it is a model-only signal (L5) and requires manual mechanistic review before any further action.

Quick Overview

Item	Content
Original Indication	Choroidal neovascularization / wet age-related macular degeneration (photodynamic therapy) — based on known clinical use, not present in the supplied license data
Predicted New Indication	Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies
TxGNN Prediction Score	99.49% (rank 5945)
Evidence Level	L5
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current evidence pack (flagged as a Blocking/High-severity data gap — see Next Steps). Based on known information, verteporfin acts as a light-activated photosensitizer, generating reactive oxygen species upon laser activation to selectively damage neovascular endothelium — this is the basis of its approved use in PDT for choroidal neovascularization. Separately from its light-dependent activity, verteporfin has also been studied as a non-light-dependent inhibitor of the YAP/TAZ transcriptional co-activators in the Hippo signaling pathway, which has drawn interest in oncology and anti-fibrotic research.

Neither of these known mechanisms — photodynamic vascular ablation or YAP/TAZ inhibition — has an established biochemical link to nuclear-DNA-encoded oxidative phosphorylation (OXPHOS) complex assembly or function, which is the defect underlying the predicted indication. The very high TxGNN score (99.49%) most likely reflects topological similarity in the knowledge graph (e.g., shared genes, pathways, or co-occurring drug/disease neighbors) rather than a substantiated pharmacological rationale. This prediction should be treated as a hypothesis-generating signal only, pending manual review of the underlying knowledge graph paths and any mitochondrial-relevant pharmacology data for verteporfin.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Germany Market Information

Verteporfin is currently not marketed in Germany, and no marketing authorizations are recorded in the evidence pack (total_licenses = 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported by zero clinical trials and zero literature (L5, model-only), and no established mechanistic pathway connects verteporfin's known pharmacology to nuclear-DNA-related OXPHOS disorders. Without any product currently marketed in Germany and with a Blocking safety data gap (no TFDA/label warnings retrieved), this candidate cannot proceed past S0.

To proceed, the following is needed:

Retrieve TFDA/EMA label warnings, contraindications, and DDI data (currently Blocking — DG001)
Retrieve verified drug MOA data from DrugBank or primary literature (currently High severity — DG002)
Manual review of the TxGNN knowledge-graph path(s) driving this prediction, to distinguish genuine mechanistic signal from graph topology artifact
Preclinical/mechanistic evidence (e.g., mitochondrial function assays) before considering any clinical hypothesis generation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.